Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies
Peggy A. Thompson,
Boreth Eam,
Nathan P. Young,
Sarah Fish,
Joan W. Chen,
Maria Barrera,
Haleigh Howard,
Ana Marı́a López-Parra,
Jolene Molter,
Jocelyn Staunton,
Blood · 2017 · 14 citations · 0 references